{"id":"W2900694112","doi":"10.1182/blood-2018-99-111370","title":"Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Leukemia; Lymphoma; Internal medicine; Immunology; Oncology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002472629,0.001098549,0.002304964,0.0003900768,0.0003286225,0.001165785,0.001028687,0.001110219,0.003758973],"category_scores_gemma":[0.001629967,0.0005322493,0.002200117,0.000513727,0.0008591053,0.0008655958,0.0004750514,0.002758981,0.0006418127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001607259,"about_ca_system_score_gemma":0.001677875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001732065,"about_ca_topic_score_gemma":0.00511653,"domain_scores_codex":[0.9991353,0.000513116,0.00004726499,0.0001071811,0.00005702909,0.0001400431],"domain_scores_gemma":[0.9985276,0.0003906693,0.0003216843,0.00008813075,0.00006393642,0.0006079563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9369863,0.01312323,0.002096603,0.000490794,0.0009745001,0.00003911423,0.00008887516,0.0007563428,0.004595055,0.00006804606,0.001165713,0.03961558],"study_design_scores_gemma":[0.6986032,0.2875553,0.009665707,0.00006665823,0.001073231,0.00009605416,0.00003970784,0.0006820984,0.0008499736,0.0001111492,0.00123315,0.00002386742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895487,0.005516859,0.0002945463,0.0004389431,0.0001659371,0.001337535,0.001150865,0.00007400943,0.001472558],"genre_scores_gemma":[0.9920015,0.002371706,0.0009153075,0.000758796,0.0002034259,0.001245434,0.001477293,0.00002673701,0.0009998747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003758973,"threshold_uncertainty_score":0.01307666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03171698714767747,"score_gpt":0.2927602090941959,"score_spread":0.2610432219465184,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}